Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Ptc Therapeutics (PTCT)

Ptc Therapeutics (PTCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference PR Newswire - Mon Jan 12, 7:30AM CST

– Strong Sephience™ (sepiapterin) launch continues with unaudited Q4 global revenue of $92.5M –

PTCT : 75.64 (-2.13%)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire - Thu Jan 8, 3:30PM CST

WARREN, N.J. , Jan. 8, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 2, 2026, the company approved 300 restricted stock units ("RSUs"), each representing...

PTCT : 75.64 (-2.13%)
PTC Therapeutics Announces Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in Japan PR Newswire - Mon Dec 22, 2025

– Indication includes all ages and the full spectrum of disease severity – – First Japan product approval for PTC –

PTCT : 75.64 (-2.13%)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire - Fri Dec 19, 2025

WARREN, N.J. , Dec. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 16, 2025, the company approved non-statutory stock options to purchase an aggregate...

PTCT : 75.64 (-2.13%)
PTC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire - Thu Dec 18, 2025

WARREN, N.J. , Dec. 18, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that CEO Matthew B. Klein, M.D., will present at the 44 th Annual J.P. Morgan Healthcare Conference...

PTCT : 75.64 (-2.13%)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire - Mon Dec 1, 2025

WARREN, N.J. , Dec. 1, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 24, 2025 , the company approved non-statutory stock options to purchase an aggregate...

PTCT : 75.64 (-2.13%)
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors GlobeNewswire - Mon Dec 1, 2025

PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation...

PTCT : 75.64 (-2.13%)
CVKD : 8.20 (-2.38%)
Sandisk Set to Join S&P 500; Upwork, First Interstate BancSystem, PTC Therapeutics to Join S&P SmallCap 600 PR Newswire - Mon Nov 24, 2025

NEW YORK , Nov. 24, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600: 

PTCT : 75.64 (-2.13%)
IPG : 24.57 (-1.96%)
SNDK : 409.24 (+5.53%)
OMC : 80.84 (+0.82%)
UPWK : 20.15 (+0.25%)
SPGI : 545.43 (+0.08%)
PINC : 28.26 (+0.32%)
GIL : 63.81 (+2.10%)
FIBK : 37.27 (+2.03%)
HBI : 6.47 (-1.82%)
GIL.TO : 88.68 (+2.19%)
PTC Therapeutics to Host R&D Day PR Newswire - Thu Nov 20, 2025

Event to take place on Dec. 2, 2025 in New York City

PTCT : 75.64 (-2.13%)
PTC Therapeutics: Q3 Earnings Snapshot AP - Tue Nov 4, 2025

PTC Therapeutics: Q3 Earnings Snapshot

PTCT : 75.64 (-2.13%)

Barchart Exclusives

As Citigroup Slashes Jobs, Should You Buy, Sell, or Hold the Dividend Stock Yielding 2%? Barchart - 1 hour ago
As part of a broader plan to cut 20,000 roles by the end of the year, Citigroup announced 1,000 cuts this week. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot